What is the current treatment of PTLD after liver transplantation?

Journal of Hepatology

Volumn 44, Issue 1, 2006, Pages 23-26

  Dufour, Jean François ^a   Fey, Martin F ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; BASILIXIMAB; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6 ANTIBODY; PREDNISONE; RITUXIMAB; THYMIDINE KINASE; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; B LYMPHOCYTE; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEVER; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECIPIENT; REMISSION; REVIEW; SURGICAL TECHNIQUE; T LYMPHOCYTE; VIRUS INFECTION;

COMBINED MODALITY THERAPY; HUMANS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; TREATMENT OUTCOME;

EID: 28844442326     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.10.009     Document Type: Review

References (33)

1. V. Leblond, and S. Choquet Lymphoproliferative disorders after liver transplantation J Hepatol 40 2004 728 735
2. D.E. Tsai, C.L. Hardy, J.E. Tomaszewski, R.M. Kotloff, K.M. Oltoff, and B.G. Somer Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients Transplantation 71 2001 1076 1088
3. M. Hurwitz, D.M. Desai, K.L. Cox, W.E. Berquist, C.O. Esquivel, and M.T. Millan Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation Pediatr Transplant 8 2004 267 272
4. F. Smets, and E.M. Sokal Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management Pediatr Transplant 6 2002 280 287
5. M.O. Serinet, E. Jacquemin, D. Habes, D. Debray, M. Fabre, and O. Bernard Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients J Pediatr Gastroenterol Nutr 34 2002 389 393
6. S. Nathanson, D. Debray, A. Delarue, and G. Deschenes Long-term survival after post-transplant lymphoproliferative disease in children Pediatr Nephrol 17 2002 668 672
7. A. Venzke, R. Ganschow, E. Grabhorn, X. Rogiers, and M. Burdelski Basiliximab monotherapy following B-cell lymphoma after pediatric liver transplantation and anti-CD20 therapy Pediatr Transplant 7 2003 404 407
8. C. Jimenez-Rivera, Y. Avitzur, A.H. Fecteau, N. Jones, D. Grant, and V.L. Ng Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma Pediatr Transplant 8 2004 243 248
9. R. Ganschow, T. Schulz, T. Meyer, D.C. Broering, and M. Burdelski Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients J Pediatr Gastroenterol Nutr 38 2004 198 203
10. D. Kogan-Liberman, M. Burroughs, S. Emre, A. Moscona, and B.L. Shneider The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience J Pediatr Gastroenterol Nutr 33 2001 445 449
11. N.R. Barshes, T.C. Lee, S.J. Karpen, L.J. Bristow, R.E. Quiros-Tejeira, and J.A. Goss Asymptomatic small bowel intussusception associated with post-transplant lymphoproliferative disease Pediatr Transplant 8 2004 196 197
12. P.W. Baron, M.A. Heneghan, P.V. Suhocki, J.D. Nuckols, J.E. Tuttle-Newhall, D.N. Howell, and P.A. Clavien Biliary stricture secondary to donor B-cell lymphoma after orthotopic liver transplantation Liver Transpl 7 2001 62 67
13. B.H. Koffman, A.S. Kennedy, M. Heyman, J. Colonna, and C. Howell Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation Int J Cancer 90 2000 104 109
14. A.A. Castellano-Sanchez, S. Li, J. Qian, A. Lagoo, E. Weir, and D.J. Brat Primary central nervous system posttransplant lymphoproliferative disorders Am J Clin Pathol 121 2004 246 253
15. S.J. Mentzer, S.P. Perrine, and D.V. Faller Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate Transpl Infect Dis 3 2001 177 185
16. S.H. Oertel, I. Anagnostopoulos, M.W. Hummel, S. Jonas, and H.B. Riess Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease Br J Haematol 118 2002 1120 1123
17. S.V. McDiarmid, S. Jordan, G.S. Kim, M. Toyoda, J.A. Goss, and J.H. Vargas Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients Transplantation 66 1998 1604 1611
18. C.L. Davis, B.L. Wood, D.E. Sabath, J.S. Joseph, C. Stehman-Breen, and V.C. Broudy Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants Transplantation 66 1998 1770 1779
19. C. Gerstenkorn, G. Jackson, F. Di Franco, O. Thomusch, and D. Talbot Outcome of PTLD in renal and liver allograft recipients Transplant Proc 33 2001 2469 2472
20. E. Borges, J.A. Ferry, and A.M. Friedmann Epstein-Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease Transplantation 73 2002 541 543
21. S. Zompi, M. Tulliez, F. Conti, V. Leblond, P. Gaulard, and P. Blanche Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases J Hepatol 32 2000 521 527
22. A.J. Grillo-Lopez, C.A. White, C. Varns, D. Shen, A. Wei, A. McClure, and B.K. Dallaire Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma Semin Oncol 26 1999 66 73
23. V. Ganne, N. Siddiqi, B. Kamaplath, C.C. Chang, E.P. Cohen, B.A. Bresnahan, and S. Hariharan Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder Clin Transplant 17 2003 417 422
24. G. Dotti, A. Rambaldi, R. Fiocchi, T. Motta, G. Torre, and P. Viero Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant Haematologica 86 2001 618 623
25. T. Berney, S. Delis, T. Kato, S. Nishida, N.K. Mittal, and J. Madariaga Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients Transplantation 74 2002 1000 1006
26. T. Haque, P.L. Amlot, N. Helling, J.A. Thomas, P. Sweny, and K. Rolles Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients J Immunol 160 1998 6204 6209
27. R. Khanna, S. Bell, M. Sherritt, A. Galbraith, S.R. Burrows, and L. Rafter Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease Proc Natl Acad Sci USA 96 1999 10391 10396
28. T. Haque, C. Taylor, G.M. Wilkie, P. Murad, P.L. Amlot, and S. Beath Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells Transplantation 72 2001 1399 1402
29. P. Comoli, M. Labirio, S. Basso, F. Baldanti, P. Grossi, and M. Furione Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication Blood 99 2002 2592 2598
30. M. Green, J. Reyes, S. Webber, and D. Rowe The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation Transpl Infect Dis 3 2001 97 103
31. E. Haddad, S. Paczesny, V. Leblond, J.M. Seigneurin, M. Stern, and A. Achkar Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial Blood 97 2001 1590 1597
32. S. Yedibela, T. Reck, G. Niedobitek, M. Gramatzki, R. Repp, W. Hohenberger, and R. Ott Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation Transpl Int 16 2003 197 201
33. E.M. Marom, H.P. McAdams, K.J. Butnor, and R.E. Coleman Positron emission tomography with fluoro-2-deoxy-d-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients J Thorac Imaging 19 2004 74 78